Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    14-September-2000      
Issue 154 Next Update - 14:00 UTC 08:00 EST    15-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya National Heart, Lung, & Blood Institute Statement On AZT And Cardiac Damage In Infants

Benefits Outweigh Risks

Since 1994, Zidovudine, or AZT, has been the officially recommended therapy for preventing the maternal to child transmission of the human immunodeficiency virus (HIV) throughout the industrialized world, and its use has been associated with a sharp decline in the incidence of AIDS in children. In the U.S., the drop in pediatric AIDS during this period has been more than 60 percent.

However, several recent studies have suggested that the use of AZT to prevent the spread of HIV from mother to child may result in cardiac abnormalities in children. Now new data from an NHLBI pediatric AIDS study provide reassuring evidence that AZT is not associated with any significant negative clinical effects on the heart. These data show no significant differences in cardiac function between children exposed to AZT and those not exposed, regardless of their HIV status.

The data are from the NHLBI's "Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) Study." They are published in the paper on "Absence of Cardiac Toxicity of Zidovudine (AZT) in Infants" that appears in the September 14, 2000 issue of the New England Journal of Medicine.

Although observational data suggest that other agents may prevent maternal to child HIV transmission, controlled studies of these agents have not been conducted, and we know little about their safety profiles. One such agent, nevirapine, has been suggested as an effective therapy in countries where pregnant women have limited access to prenatal care and may benefit from a simpler regimen.

Until such time as another agent is identified that can match the record of AZT in preventing maternal to child HIV transmission, the new data strongly suggest that the benefits of using AZT outweigh any possible cardiac risks to the infant, and physicians should continue using this therapy to treat pregnant women with HIV.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.